AGTC up +20.85% percent right now. $AGTC High is at 27.04 and the Low 21.39 with current volume of 88,700.
Recent News posted below.
AGTC Applied Genetic Technologies Co Recent Headline News
American Gilsonite to Announce 3rd Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 10:14AM CST
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the third quarter ended September 30, 2014 to the Company's Intralinks investor site on Wednesday, November 12, 2014.
AGTC: 26.20 (+4.52)
Data Published in Human Gene Therapy Clinical Development Support Safety of AGTC's AAV Vector Manufacturing Process
GlobeNewswire - Mon Nov 03, 6:01AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the publication of data that further validate the safety of the company's proprietary method for manufacturing adeno-associated viral (AAV) vectors. The publication, "Herpes Simplex Virus Clearance During Purification of a Recombinant Adeno-Associated Virus Serotype 1 Vector" appears in the October 2014 issue of Human Gene Therapy Clinical Development.
AGTC: 26.20 (+4.52)
AGTC President and CEO Sue Washer Receives OIS@AAO Innovator Award
GlobeNewswire - Thu Oct 16, 8:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, AGTC president and CEO is this year's recipient of the OIS@AAO Innovator Award.
AGTC: 26.20 (+4.52)
AGTC Named BioFlorida Company of the Year
GlobeNewswire - Tue Oct 14, 12:00PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced BioFlorida has awarded it the 2014 David J. Gury Company of the Year Award.
AGTC: 26.20 (+4.52)
AGTC CEO to Participate in Panel Discussions at Upcoming Conferences
GlobeNewswire - Thu Oct 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, AGTC President and CEO, will present at two upcoming conferences.
AGTC: 26.20 (+4.52)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Mon Oct 06, 8:31AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
AGTC: 26.20 (+4.52), INO: 11.23 (+0.16), PTLA: 27.39 (-0.33)
AGTC Leadership to Present at Upcoming Healthcare Conferences
GlobeNewswire - Mon Sep 29, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will present at two upcoming conferences.
AGTC: 26.20 (+4.52)
AGTC Announces Financial Results for the Quarter and Fiscal Year Ended June 30, 2014
GlobeNewswire - Fri Sep 26, 3:01PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the quarter and fiscal year ended June 30, 2014.
AGTC: 26.20 (+4.52)
Two Promising Gene Therapy Stocks Tackling Eye Disease
at The Street - Tue Sep 09, 8:04AM CDT
Investors will get a first look at data from an early stage study of an Applied Genetic therapy on Friday.
AGTC: 26.20 (+4.52), AAVL: 35.00 (+0.25), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
AGTC to Participate in Emerging Ophthalmology Therapies Panel at Citi 9th Annual Biotech Conference
GlobeNewswire - Tue Aug 26, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapy products for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO will participate at the Citi 9th Annual Biotech Conference on Thursday, September 4 in a panel discussion entitled "Emerging Ophthalmology Therapies: Getting 20/20 on the Drug Landscape." The panel will be moderated by Citi analysts Yaron Werber and Liav Abraham.
AGTC: 26.20 (+4.52)
AGTC to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 05, 6:07AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will participate in upcoming investor conferences.
AGTC: 26.20 (+4.52)
AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Aug 04, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC) announced today the closing on July 30, 2014 of its public offering of 2,000,000 shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts, and the exercise in full by the underwriters of their option to purchase 300,000 additional shares of common stock at $15.00 per share, which closed on August 1, 2014. AGTC offered all of the shares of common stock. The company plans to use the net proceeds from the offering to fund preclinical investigation and Phase 1/2 trials of potential product candidates for treatment of wet AMD, to expand its manufacturing capabilities and create a pilot manufacturing group, to in-license, acquire or invest in complementary gene therapy, technologies, products or assets, and for working capital and other general corporate purposes.
AGTC: 26.20 (+4.52)
Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis
PR Newswire - Wed Jul 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Medivation, Inc. (NASDAQ: MDVN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5255-100free.
AGTC: 26.20 (+4.52), MDVN: 112.77 (+7.82), CLVS: 58.31 (-0.26), FOLD: 5.72 (-0.16), KERX: 16.73 (-0.47)
Applied Genetic Technologies Corporation (AGTC) Looks Strong as Stock Surges 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:44AM CDT
Applied Genetic Technologies Corporation (AGTC) was a big mover last session, as the company saw its shares shoot up over 15% on the day.
AGTC: 26.20 (+4.52), ENZ: 4.94 (-0.13), FOLD: 5.72 (-0.16)
4 Stocks Rising on Unusual Volume
at The Street - Mon Jul 28, 6:20AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
AGTC: 26.20 (+4.52), PFPT: 44.00 (+1.25), CYN: 79.46 (-0.22)
AGTC Announces Pricing of Public Offering
GlobeNewswire - Thu Jul 24, 6:05PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC) today announced the pricing of its public offering of 2,000,000 shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts. All of the common stock is being offered by AGTC. In addition, AGTC has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares at the public offering price to cover over-allotments, if any. The company plans to use the net proceeds from the offering to fund preclinical investigation and Phase 1/2 trials of potential product candidates for treatment of wet AMD, to expand its manufacturing capabilities and create a pilot manufacturing group, to in-license, acquire or invest in complementary gene therapy, technologies, products or assets, and for working capital and other general corporate purposes.
AGTC: 26.20 (+4.52)
New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health
PR Newswire - Wed Jul 02, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.
AGTC: 26.20 (+4.52), CRIS: 1.30 (+0.01), HALO: 9.12 (-0.03), ENZ: 4.94 (-0.13), MGLN: 59.65 (-0.45)
AGTC Appoints Matthew Feinsod, MD, as Product Development Officer
GlobeNewswire - Tue Jul 01, 6:10AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the appointment of Matthew Feinsod, MD, to the position of Product Development Officer.
AGTC: 26.20 (+4.52)
AGTC Appoints David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to Its Board of Directors
GlobeNewswire - Mon Jun 30, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has appointed David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to the company's Board of Directors.
AGTC: 26.20 (+4.52)
Recent News posted below.
AGTC Applied Genetic Technologies Co Recent Headline News
American Gilsonite to Announce 3rd Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 10:14AM CST
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the third quarter ended September 30, 2014 to the Company's Intralinks investor site on Wednesday, November 12, 2014. AGTC: 26.20 (+4.52)
Data Published in Human Gene Therapy Clinical Development Support Safety of AGTC's AAV Vector Manufacturing Process
GlobeNewswire - Mon Nov 03, 6:01AM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the publication of data that further validate the safety of the company's proprietary method for manufacturing adeno-associated viral (AAV) vectors. The publication, "Herpes Simplex Virus Clearance During Purification of a Recombinant Adeno-Associated Virus Serotype 1 Vector" appears in the October 2014 issue of Human Gene Therapy Clinical Development.
AGTC: 26.20 (+4.52)
AGTC President and CEO Sue Washer Receives OIS@AAO Innovator Award
GlobeNewswire - Thu Oct 16, 8:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, AGTC president and CEO is this year's recipient of the OIS@AAO Innovator Award.
AGTC: 26.20 (+4.52)
AGTC Named BioFlorida Company of the Year
GlobeNewswire - Tue Oct 14, 12:00PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced BioFlorida has awarded it the 2014 David J. Gury Company of the Year Award.
AGTC: 26.20 (+4.52)
AGTC CEO to Participate in Panel Discussions at Upcoming Conferences
GlobeNewswire - Thu Oct 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, AGTC President and CEO, will present at two upcoming conferences.
AGTC: 26.20 (+4.52)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Mon Oct 06, 8:31AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
AGTC: 26.20 (+4.52), INO: 11.23 (+0.16), PTLA: 27.39 (-0.33)
AGTC Leadership to Present at Upcoming Healthcare Conferences
GlobeNewswire - Mon Sep 29, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will present at two upcoming conferences.
AGTC: 26.20 (+4.52)
AGTC Announces Financial Results for the Quarter and Fiscal Year Ended June 30, 2014
GlobeNewswire - Fri Sep 26, 3:01PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the quarter and fiscal year ended June 30, 2014.
AGTC: 26.20 (+4.52)
Two Promising Gene Therapy Stocks Tackling Eye Disease
at The Street - Tue Sep 09, 8:04AM CDT
Investors will get a first look at data from an early stage study of an Applied Genetic therapy on Friday.
AGTC: 26.20 (+4.52), AAVL: 35.00 (+0.25), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
AGTC to Participate in Emerging Ophthalmology Therapies Panel at Citi 9th Annual Biotech Conference
GlobeNewswire - Tue Aug 26, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapy products for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO will participate at the Citi 9th Annual Biotech Conference on Thursday, September 4 in a panel discussion entitled "Emerging Ophthalmology Therapies: Getting 20/20 on the Drug Landscape." The panel will be moderated by Citi analysts Yaron Werber and Liav Abraham.
AGTC: 26.20 (+4.52)
AGTC to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 05, 6:07AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will participate in upcoming investor conferences.
AGTC: 26.20 (+4.52)
AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Aug 04, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC) announced today the closing on July 30, 2014 of its public offering of 2,000,000 shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts, and the exercise in full by the underwriters of their option to purchase 300,000 additional shares of common stock at $15.00 per share, which closed on August 1, 2014. AGTC offered all of the shares of common stock. The company plans to use the net proceeds from the offering to fund preclinical investigation and Phase 1/2 trials of potential product candidates for treatment of wet AMD, to expand its manufacturing capabilities and create a pilot manufacturing group, to in-license, acquire or invest in complementary gene therapy, technologies, products or assets, and for working capital and other general corporate purposes.
AGTC: 26.20 (+4.52)
Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis
PR Newswire - Wed Jul 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Medivation, Inc. (NASDAQ: MDVN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5255-100free.
AGTC: 26.20 (+4.52), MDVN: 112.77 (+7.82), CLVS: 58.31 (-0.26), FOLD: 5.72 (-0.16), KERX: 16.73 (-0.47)
Applied Genetic Technologies Corporation (AGTC) Looks Strong as Stock Surges 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:44AM CDT
Applied Genetic Technologies Corporation (AGTC) was a big mover last session, as the company saw its shares shoot up over 15% on the day.
AGTC: 26.20 (+4.52), ENZ: 4.94 (-0.13), FOLD: 5.72 (-0.16)
4 Stocks Rising on Unusual Volume
at The Street - Mon Jul 28, 6:20AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
AGTC: 26.20 (+4.52), PFPT: 44.00 (+1.25), CYN: 79.46 (-0.22)
AGTC Announces Pricing of Public Offering
GlobeNewswire - Thu Jul 24, 6:05PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC) today announced the pricing of its public offering of 2,000,000 shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts. All of the common stock is being offered by AGTC. In addition, AGTC has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares at the public offering price to cover over-allotments, if any. The company plans to use the net proceeds from the offering to fund preclinical investigation and Phase 1/2 trials of potential product candidates for treatment of wet AMD, to expand its manufacturing capabilities and create a pilot manufacturing group, to in-license, acquire or invest in complementary gene therapy, technologies, products or assets, and for working capital and other general corporate purposes.
AGTC: 26.20 (+4.52)
New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health
PR Newswire - Wed Jul 02, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.
AGTC: 26.20 (+4.52), CRIS: 1.30 (+0.01), HALO: 9.12 (-0.03), ENZ: 4.94 (-0.13), MGLN: 59.65 (-0.45)
AGTC Appoints Matthew Feinsod, MD, as Product Development Officer
GlobeNewswire - Tue Jul 01, 6:10AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the appointment of Matthew Feinsod, MD, to the position of Product Development Officer.
AGTC: 26.20 (+4.52)
AGTC Appoints David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to Its Board of Directors
GlobeNewswire - Mon Jun 30, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has appointed David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to the company's Board of Directors.
AGTC: 26.20 (+4.52)
